A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

This early-phase study tests a new experimental drug called JNJ-95566692 for people with B-cell non-Hodgkin lymphomas and related blood cancers that have returned after prior treatment or stopped responding. **You may be eligible if...** - You have a confirmed B-cell non-Hodgkin lymphoid malignancy (such as certain lymphomas) per the 2022 WHO classification - Your cancer has relapsed or is refractory (not responding) and no better approved options are available - You have received at least 2 prior lines of therapy, including an anti-CD20 antibody-based chemotherapy regimen - OR you have had at least one prior treatment but are not eligible for or cannot access standard second-line therapies like CAR-T **You may NOT be eligible if...** - You have adequate access to and eligibility for standard second-line therapies - Your cancer does not match the required diagnosis - You have not received the required prior treatments Talk to your doctor to see if this trial is right for you.